External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices

Article Medical Laboratory Technology

Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma

Raza S. Hoda et al.

Summary: The study revealed substantial agreement among 8 pathologists in the assessment of PD-L1 SP142 IHC in breast carcinoma cases at a single institution, with few cases showing discrepancies in interpretation results. Further research is needed to understand the basis for inconsistent findings.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)

Add to Collection

Review Oncology

Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer Update for 2020

Lauren C. Brown et al.

Summary: Triple-negative breast cancer (TNBC) has poorer outcomes compared to other subtypes, and there is a lack of established treatment options beyond chemotherapy. Biomarkers are needed to improve prognosis and guide therapy, with tumor-infiltrating lymphocytes gaining relevance as an immunological biomarker in this field.

CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Leisha A. Emens et al.

Summary: Understanding the impact of tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors in metastatic triple-negative breast cancer may help optimize patient and treatment selection. The study found that PD-L1 expression and CD8-positive cells had an influence on the efficacy of immunotherapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Review Oncology